New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!
Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!
Click below to watch the presentation.
Related Posts
Abterra Bio awarded $1.8M NIH SBIR to extend antibody repertoire analysis software, REPTOR
Next-generation sequencing is a valuable readout for antibody discovery campaigns, but current software does not address the real pain points of analysis. Abterra Biosciences has developed Reptor software to enable visualization and interrogation of large-scale...
Limit of Detection – Serum Antibody Analysis
In this blog post, we evaluate the limit of detection for serum antibody analysis achieved by Alicanto using spike ins.
VHH Antibody Repertoire to Phage Library Comparison
We used Reptor to compare the VHH antibody repertoire from an immunized llama to a phage library constructed from the same source.
Get In Touch